COHANCE vs VALIANTLAB: Stock Comparison
Cohance Lifesciences Limited is the larger company by market capitalisation. Cohance Lifesciences Limited shows a higher ROE, lower leverage and a higher ROCE, while Valiant Laboratories Ltd shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
COHANCE leads 5; VALIANTLAB leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | COHANCE | VALIANTLAB |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | COHANCE | VALIANTLAB |
|---|---|---|
| Live Price | ₹463 | ₹95.74 |
| Day Change | -2.64% | 4.45% |
| Volume | 16.39 L | 3.6 L |
| 52-Week High | ₹1,038.9 | ₹95.1 |
| 52-Week Low | ₹266.7 | ₹49.51 |
| Distance from 52W High | -55.43% | 0.67% |
Valuation
| Metric | COHANCE | VALIANTLAB |
|---|---|---|
| Market Cap | ₹17,71,425.64 L Cr | ₹508 Cr |
| P/E Ratio | 167.27x | 29.56x |
| P/B Ratio | 4.55x | 1.52x |
| EPS | ₹2.78 | ₹2.95 |
| Book Value | ₹102.03 | ₹57.2 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | COHANCE | VALIANTLAB |
|---|---|---|
| Revenue Growth (TTM YoY) | -26.3% | 0% |
| EPS Growth (TTM YoY) | -89% | 0% |
| Qtr Sales Growth | -26.3% | 146% |
| Qtr Profit Growth | -86.6% | 1,059% |
Profitability & Leverage
| Metric | COHANCE | VALIANTLAB |
|---|---|---|
| ROE | 7.04% | -1.2% |
| ROCE | 8.35% | 0.75% |
| Net Margin | 7.9% | -1.38% |
| Operating Margin | 18.8% | 10.9% |
| Debt to Equity | 0.1x | 0.15x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | COHANCE | VALIANTLAB |
|---|---|---|
| Promoter Holding | 0% | 74.94% |
| FII Holding | 6.5%▲ 0.91 pp | 0%▼ 0.2 pp |
| DII Holding | 20.09%▼ 1.7 pp | 0% |
| Public Holding | 15.92%▲ 0.8 pp | 25.06%▲ 0.2 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cohance Lifesciences Limited and Valiant Laboratories Ltd.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.